P-137 Phase 1/1b study evaluating KIN-3248, a next-generation, irreversible pan-FGFR inhibitor (FGFRi), in patients (pts) with advanced cholangiocarcinoma (CCA) and other solid tumors harboring FGFR2 and/or FGFR3 gene alterations
- Resource Type
- Abstract
- Source
- In
Annals of Oncology June 2023 34 Supplement 1:S63-S64 - Subject
- Language
- ISSN
- 0923-7534